Avantor
- Market cap
- 10.38B
- P/E (TTM)i
- -18.06
- P/Bi
- 1.84
- EPSi
- -0.78
- Div yieldi
- 0.00%
- 52W posi
- 89%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Medical Instruments & Supplies
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Avantor (AVTR) | 10.38B | -18.06 | 1.84 | 0.00% |
| Intuitive Surgical (ISRG) | 146.44B | 47.54 | 8.06 | 0.00% |
| Becton Dickinson & Co (BDX) | 49.07B | 54.43 | 2.01 | 2.33% |
| ResMed (RMD) | 31.78B | 21.67 | 4.83 | 1.06% |
| Medline (MDLN) | 31.10B | 67.27 | 2.69 | 0.00% |
| Alcon (ALC) | 30.45B | 48.09 | 1.41 | 0.56% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 25.8% below Morningstar's fair value estimate.
Fair value
Avantor Inc is assigned a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 18% discount to our quantitative fair value estimate of $19.31 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 1.3 sits in the top 30% compared with peers globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be cheap.
Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -2.9%, a core component of profitability, lies in the bottom 20% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.